Objective To study changes of treatment in preterm infants with respiratory distress syndrome (RDS) during 1998-2012. Methods Retrospective observational study of infants, <34 weeks gestation, born between January 1998 and December 2012.A group was the cases during the first 7 years(n=63), and B group was the cases during the next 8 years(n=151).Perinatal data, birth history treatment (including respiratory support, surfactant therapy and doses), complications and outcomes were compared. Results The birth weight of B group was (1 284.50±252.153)g, significantly lower than A group [(1 424.27±329.44)g](t=3.292, P<0.001).The amount of surfactant in group was (169.66±57.97) mg, significantly lower than that of B group [(195.00±59.87) mg](P=0.041).The requirement of intubation ventilation support in A group was 39 cases (90.7%), higher than 85 cases in B group (70.8%)(χ2=6.86, P<0.01).In group B, 33 cases (27.5%) developed BPD, which was more than 4 cases (9.3%) in A group (χ2=5.97, P=0.02).The length of hospitalization, NICU stay and oxygen dependence in B group were longer than A group.The mortality of B group was lower than A group, 11.7% versus 27.9% (χ2=6.23, P=0.01). Conclusion In the last decades, exogenous surfactant replacement has been established as an effective and safe therapy in RDS preterm infants.
Key words
respiratory distress syndrome /
surfactant /
preterm infants
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Teksam O, Kale G.The effects of surfactant and antenatal corticosteroid treatment on the pulmonary pathology of preterm infants with respiratory distress syndrome[J].Pathol Res Pract, 2009, 205(1):35-41.
[2] Halliday HL.Surfactants:past, present and future[J].J Perinatol, 2008, 28(S):47-56.
[3] Sweet DG, Carnielli V, Greisen G, et al.European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update[J].Neonatology, 2010, 97:402-417.
[4] Nkadi PO, Merritt TA, Pillers DM.An overview of pulmonary surfactant in the neonate:genetics, metabolism, and the role of surfactant in health and disease[J].Mol Genet Metab, 2009, 97(2):95-101.
[5] Engle WA.The Committee on Fetus and Newborn, Surfactant-replacement therapy for respiratory distress in the preterm and term neonate[J].Pediatrics, 2008, 121:419-432.
[6] 李杰, 樊寻梅, 宋国维, 等.肺表面活性制剂治疗新生儿呼吸窘迫综合征多中心临床观察[J].中华儿科杂志, 2000, 38(6):344-347.
[7] Soll R, Ozek E.Prophylactic protein-free synthetic surfactant for preventing morbidity and mortality in preterm infants[J].Cochrane Database Syst Rev, 2010, 20(1):CD001079.
[8] Yen TA, Wang CC, Hsieh WS, et al.Short-term outcome of pulmonary hemorrhage in very-low-birth-weight preterm infants[J].Pediatr Neonatol, 2013, 54(5):330-4.
[9] Strauss T, Rozenzweig N, Rosenberg N, et al.Surfactant impairs coagulation in-vitro:a risk factor for pulmonary hemorrhage?[J].Thromb Res, 2013, 132(5):599-603.
[10] Finer NN.Surfactant use for neonatal lung injury:beyond respiratory distress syndrome[J].Paediatric Respiratory Reviews, 2004, 5(S):289-297.
PDF(547 KB)
